Cargando…

Evaluating the viral clearance ability of continuous monoclonal antibody purification steps, in order to inactivate and/or remove four model viruses

BACKGROUND AND OBJECTIVES: Viral clearance studies are an essential part of a manufacturer’s plan to ensure the safety of an injectable biologic product. In this way, viral safety is a critical quality attribute for biologics such as monoclonal antibodies (Mabs). Evaluation of virus purification by...

Descripción completa

Detalles Bibliográficos
Autores principales: Rasouli-Nejad Mousavi, Seyed Mohammad, Hosseini, Seyed Masoud, Ansari, Samira
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Tehran University of Medical Sciences 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10628082/
https://www.ncbi.nlm.nih.gov/pubmed/37941874
http://dx.doi.org/10.18502/ijm.v15i5.13877
_version_ 1785131676998828032
author Rasouli-Nejad Mousavi, Seyed Mohammad
Hosseini, Seyed Masoud
Ansari, Samira
author_facet Rasouli-Nejad Mousavi, Seyed Mohammad
Hosseini, Seyed Masoud
Ansari, Samira
author_sort Rasouli-Nejad Mousavi, Seyed Mohammad
collection PubMed
description BACKGROUND AND OBJECTIVES: Viral clearance studies are an essential part of a manufacturer’s plan to ensure the safety of an injectable biologic product. In this way, viral safety is a critical quality attribute for biologics such as monoclonal antibodies (Mabs). Evaluation of virus purification by downstream processes is a key component of risk mitigation. In this study, the capability of continuous monoclonal antibody purification steps was evaluated in the process of instant monoclonal antibody purification in different stages of purification, and the amount of reduction or inactivation of each step was determined. MATERIALS AND METHODS: Four enveloped and non-enveloped viral models VSV, Reovirus, EMCV, and HSV1 were used for spiking in selected samples in the designated tests, to have a comprehensive examination of the ability to clear the virus such as the type of genetic material, chemical resistance, and particle size. A TCID(50) and qPCR methods were used to measure viral reduction. Two cell lines, Vero (African green monkey kidney) and L929 (Mouse fibroblast) were used for 4 model viruses propagation. The steps that were evaluated included 4 steps monoclonal antibody purification; cation exchange chromatography, acidic pH treatment, affinity chromatography, and nanofiltration. RESULTS: The nano-filter stage showed the highest viral reduction and cation exchange chromatography showed the lowest reduction. The cumulative decrease using TCID(50) is equal to 19.27 [log10] for all steps and for the qPCR method is equal to 12.47 [log10] in three steps of nano-filter, affinity chromatography, and ion exchange chromatography. CONCLUSION: The overall average reduction coefficient for all four model viruses is significantly high, which indicates the high capacity of the monoclonal antibody production process in inactivating and removing viruses leads to reducing the load of all four model viruses.
format Online
Article
Text
id pubmed-10628082
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Tehran University of Medical Sciences
record_format MEDLINE/PubMed
spelling pubmed-106280822023-11-08 Evaluating the viral clearance ability of continuous monoclonal antibody purification steps, in order to inactivate and/or remove four model viruses Rasouli-Nejad Mousavi, Seyed Mohammad Hosseini, Seyed Masoud Ansari, Samira Iran J Microbiol Original Article BACKGROUND AND OBJECTIVES: Viral clearance studies are an essential part of a manufacturer’s plan to ensure the safety of an injectable biologic product. In this way, viral safety is a critical quality attribute for biologics such as monoclonal antibodies (Mabs). Evaluation of virus purification by downstream processes is a key component of risk mitigation. In this study, the capability of continuous monoclonal antibody purification steps was evaluated in the process of instant monoclonal antibody purification in different stages of purification, and the amount of reduction or inactivation of each step was determined. MATERIALS AND METHODS: Four enveloped and non-enveloped viral models VSV, Reovirus, EMCV, and HSV1 were used for spiking in selected samples in the designated tests, to have a comprehensive examination of the ability to clear the virus such as the type of genetic material, chemical resistance, and particle size. A TCID(50) and qPCR methods were used to measure viral reduction. Two cell lines, Vero (African green monkey kidney) and L929 (Mouse fibroblast) were used for 4 model viruses propagation. The steps that were evaluated included 4 steps monoclonal antibody purification; cation exchange chromatography, acidic pH treatment, affinity chromatography, and nanofiltration. RESULTS: The nano-filter stage showed the highest viral reduction and cation exchange chromatography showed the lowest reduction. The cumulative decrease using TCID(50) is equal to 19.27 [log10] for all steps and for the qPCR method is equal to 12.47 [log10] in three steps of nano-filter, affinity chromatography, and ion exchange chromatography. CONCLUSION: The overall average reduction coefficient for all four model viruses is significantly high, which indicates the high capacity of the monoclonal antibody production process in inactivating and removing viruses leads to reducing the load of all four model viruses. Tehran University of Medical Sciences 2023-10 /pmc/articles/PMC10628082/ /pubmed/37941874 http://dx.doi.org/10.18502/ijm.v15i5.13877 Text en Copyright © 2023 The Authors. Published by Tehran University of Medical Sciences https://creativecommons.org/licenses/by-nc/4.0/This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International license (https://creativecommons.org/licenses/by-nc/4.0/). Non-commercial uses of the work are permitted, provided the original work is properly cited.
spellingShingle Original Article
Rasouli-Nejad Mousavi, Seyed Mohammad
Hosseini, Seyed Masoud
Ansari, Samira
Evaluating the viral clearance ability of continuous monoclonal antibody purification steps, in order to inactivate and/or remove four model viruses
title Evaluating the viral clearance ability of continuous monoclonal antibody purification steps, in order to inactivate and/or remove four model viruses
title_full Evaluating the viral clearance ability of continuous monoclonal antibody purification steps, in order to inactivate and/or remove four model viruses
title_fullStr Evaluating the viral clearance ability of continuous monoclonal antibody purification steps, in order to inactivate and/or remove four model viruses
title_full_unstemmed Evaluating the viral clearance ability of continuous monoclonal antibody purification steps, in order to inactivate and/or remove four model viruses
title_short Evaluating the viral clearance ability of continuous monoclonal antibody purification steps, in order to inactivate and/or remove four model viruses
title_sort evaluating the viral clearance ability of continuous monoclonal antibody purification steps, in order to inactivate and/or remove four model viruses
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10628082/
https://www.ncbi.nlm.nih.gov/pubmed/37941874
http://dx.doi.org/10.18502/ijm.v15i5.13877
work_keys_str_mv AT rasoulinejadmousaviseyedmohammad evaluatingtheviralclearanceabilityofcontinuousmonoclonalantibodypurificationstepsinordertoinactivateandorremovefourmodelviruses
AT hosseiniseyedmasoud evaluatingtheviralclearanceabilityofcontinuousmonoclonalantibodypurificationstepsinordertoinactivateandorremovefourmodelviruses
AT ansarisamira evaluatingtheviralclearanceabilityofcontinuousmonoclonalantibodypurificationstepsinordertoinactivateandorremovefourmodelviruses